By Chris Wack

Synthorx Inc. (THOR) shares almost tripled to $68.05 in early trading after Sanofi SA (SAN.FR) said it was buying the clinical-stage biotechnology for $68 a share in cash.

The deal has an equity value of about $2.5 billion, and is expected to close in the first quarter of next year.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

December 09, 2019 10:13 ET (15:13 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Synthorx (NASDAQ:THOR)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024 Click aqui para mais gráficos Synthorx.
Synthorx (NASDAQ:THOR)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024 Click aqui para mais gráficos Synthorx.